0001377121
false
0001377121
2023-08-03
2023-08-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2023
PROTAGONIST THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
|
001-37852 |
|
98-0505495 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark, California 94560-1160
(Address of principal executive offices,
including zip code)
(510) 474-0170
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
Common Stock, par value $0.00001 |
|
PTGX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations
and Financial Condition.
On August 3, 2023, Protagonist
Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2023. A copy of the press release titled
“Protagonist Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update” is furnished pursuant
to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits
The information in this report, including the exhibit hereto, shall
not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein
and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission
made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language
in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Protagonist Therapeutics, Inc. |
Dated: August 3, 2023 |
|
|
|
|
By: |
/s/ Asif Ali |
|
|
Asif Ali |
|
|
Chief Financial Officer |
Exhibit 99.1
Protagonist Reports
Second Quarter 2023 Financial Results and Provides Corporate Update
Positive topline results from the Phase 2b FRONTIER
1 study of JNJ-2113 (formerly PN-235), the first and only IL-23 receptor antagonist oral peptide drug candidate for the treatment of moderate-to-severe
plaque psoriasis, presented at the World Congress of Dermatology.
JNJ-2113 now advances toward a Phase 3 study
in moderate-to-severe psoriasis and a Phase 2b study in ulcerative colitis.
Positive data from the randomized withdrawal
portion of the Phase 2 REVIVE study of rusfertide in polycythemia vera (PV) presented as a late breaker at the annual Congress of the
European Hematology Association (EHA2023); the global Phase 3 VERIFY study continues, with sites recruiting globally.
NEWARK, Calif., August 3, 2023 – Protagonist
Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today reported financial results for the second
quarter ended June 30, 2023, and provided a corporate update.
“The second quarter of 2023 was transformative for Protagonist,
marked by the disclosure of strongly positive data from FRONTIER 1, a Phase 2b study of JNJ-2113, at the World Congress of Dermatology,
and the decision by our partner, Janssen, to move forward into a Phase 3 clinical program in psoriasis and a Phase 2b study in ulcerative
colitis,” said Dinesh V. Patel, Ph.D., President and CEO of Protagonist. “JNJ-2113 is a first-in-class and only oral IL-23
receptor antagonist peptide that has the potential to lead the field of oral therapy for psoriasis. Today, a significant number of people
living with moderate-to-severe plaque psoriasis are eligible for, but are still not receiving, advanced therapies, and JNJ-2113 can potentially
offer a highly convenient, effective and safe solution to a broad category of eligible individuals.”
“We
have also made impressive strides forward in the clinical development of our fully owned asset, rusfertide, in polycythemia vera,”
Dr. Patel continued. “The Phase 2 REVIVE study results were presented to a large audience as a late breaker at EHA2023. The
Phase 3 VERIFY clinical trial is continuing to enroll study participants at sites globally, with enrollment completion projected by the
end of the first quarter of 2024. Our cash position remains strong, with estimated cash runway through end of 2025. This estimate does
not include the potential $200 million in milestones associated with a successful Phase 3 study, NDA filing, and approval of JNJ-2113
in psoriasis.”
Q2 and Recent Corporate Highlights
| · | Positive Phase 2b FRONTIER 1 topline results were presented at the World
Congress of Dermatology in Singapore in July 2023. All primary and secondary efficacy endpoints were achieved in the study, which
evaluated five different dosing regimens of JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis. |
| · | JNJ-2113 is a novel oral IL-23R antagonist peptide which binds with high
affinity to the IL-23 receptor. |
| · | In the FRONTIER 1 study, a greater proportion of patients who received JNJ-2113
achieved Psoriasis Area and Severity Index (PASI) 75 (primary endpoint), as well as PASI 90 and PASI 100 (75, 90 and 100 percent improvement
in skin lesions as measured by PASI, respectively), compared to placebo, at week 16. |
| · | 78.6 percent, 59.5 percent and 40.5 percent of adult patients who received
JNJ-2113 at 100 mg twice daily achieved PASI 75, 90 and 100, respectively, at week 16. |
| · | Five treatment groups were evaluated in the study, ranging from 25 mg once
daily to 100 mg twice daily. |
| · | Treatment was generally well tolerated, and the proportions of patients with
adverse events were comparable between patient groups. |
| · | The proportion of participants experiencing one or more adverse events was
52.4 percent in the combined JNJ-2113 group and 51.2 percent in the placebo group. |
| · | JNJ-2113 is advancing into Phase 3 development for moderate-to-severe plaque
psoriasis and in a Phase 2b clinical trial for adults living with ulcerative colitis. |
| · | Pre-clinical and Phase 1 data for JNJ-2113 were presented at the International
Societies for Investigative Dermatology meeting in Tokyo, Japan in May 2023, showing selective systemic IL-23 pathway inhibition
in pre-clinical rat models and systemic pharmacodynamic activity in healthy human volunteers in a Phase 1 trial. |
| · | Positive topline results from the blinded, placebo-controlled, randomized
withdrawal portion of the Phase 2 REVIVE study of rusfertide in polycythemia vera were presented in Frankfurt, Germany in June 2023
at EHA2023. |
| · | The Company completed a $115 million equity financing in April 2023. |
Second Quarter 2023 Financial Results
| · | Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of June 30, 2023,
were $313.4 million. |
| · | License and Collaboration Revenue: License and collaboration revenue was zero for the three and six months ended June 30,
2023 as we completed our performance obligation associated with the Janssen License and Collaboration Agreement as of June 30, 2022.
License and collaboration revenue for the three and six months ended June 30, 2022 was $0.9 million and $26.6 million, respectively.
The six months to June 30, 2022 included a one-time $25.0 million milestone earned by the Company following the dosing of the third
patient in the Janssen Phase 2b FRONTIER 1 clinical trial of JNJ-2113. |
| · | Research and Development ("R&D") Expenses: R&D expenses were $33.2 million and $60.6 million for the three
and six months ended June 30, 2023, respectively, as compared to $34.6 million and $70.9 million for the same periods in 2022. The
decreases in R&D expenses from prior year periods was primarily due to decreases in PN-943 expenses and costs related to the completion
of PN-232 Phase 1 trials, partially offset by an increase in rusfertide expenses related primarily to the Phase 3 VERIFY clinical trial. |
| · | General and Administrative ("G&A") Expenses: G&A expenses were $9.2 million and $17.8 million for the three
and six months ended June 30, 2023, respectively, as compared to $7.7 million and $18.2 million for the same periods in 2022. The
increase in G&A expenses from the prior year quarter was primarily due to increases in payroll and stock-based compensation and general
expenses. The decrease in G&A expenses from the prior year was primarily due to one-time costs incurred in the first quarter of 2022. |
| · | Net Loss: Net loss was $38.5 million, or $0.68 per share, for the three months ended June 30, 2023 as compared to a net
loss of $41.0 million, or $0.84 per share, for the three months ended June 30, 2022. Net loss was $72.2 million, or $1.34 per share,
for the six months ended June 30, 2023 as compared to a net loss of $62.0 million, or $1.27 per share, for the six months ended June 30,
2022. |
PROTAGONIST THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations
(Unaudited)
(Amounts in thousands except share and per
share data)
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
License and collaboration revenue | |
$ | - | | |
$ | 859 | | |
$ | - | | |
$ | 26,581 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development (1) | |
| 33,182 | | |
| 34,611 | | |
| 60,598 | | |
| 70,929 | |
General and administrative (1) | |
| 9,172 | | |
| 7,691 | | |
| 17,777 | | |
| 18,206 | |
Total operating expenses | |
| 42,354 | | |
| 42,302 | | |
| 78,375 | | |
| 89,135 | |
Loss from operations | |
| (42,354 | ) | |
| (41,443 | ) | |
| (78,375 | ) | |
| (62,554 | ) |
Interest income | |
| 3,913 | | |
| 484 | | |
| 6,404 | | |
| 652 | |
Other expense, net | |
| (19 | ) | |
| (78 | ) | |
| (214 | ) | |
| (65 | ) |
Net loss | |
$ | (38,460 | ) | |
$ | (41,037 | ) | |
$ | (72,185 | ) | |
$ | (61,967 | ) |
Net loss per share, basic and diluted | |
$ | (0.68 | ) | |
$ | (0.84 | ) | |
$ | (1.34 | ) | |
$ | (1.27 | ) |
Weighted-average shares used to compute net loss per share, basic and diluted | |
| 56,775,742 | | |
| 49,049,902 | | |
| 53,691,965 | | |
| 48,902,047 | |
| (1) | Amount includes non-cash stock-based compensation expense. |
PROTAGONIST THERAPEUTICS, INC.
Stock-based Compensation (Unaudited)
(In thousands)
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Research and development | |
$ | 4,809 | | |
$ | 4,106 | | |
$ | 9,391 | | |
$ | 7,432 | |
General and administrative | |
| 3,534 | | |
| 2,699 | | |
| 6,536 | | |
| 5,308 | |
Total stock-based compensation expense | |
$ | 8,343 | | |
$ | 6,805 | | |
$ | 15,927 | | |
$ | 12,740 | |
PROTAGONIST THERAPEUTICS, INC.
(Unaudited)
Selected Consolidated Balance Sheet Data
(In thousands)
| |
June 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Cash, cash equivalents and marketable securities | |
$ | 313,401 | | |
$ | 237,355 | |
Working capital | |
| 290,543 | | |
| 211,898 | |
Total assets | |
| 320,466 | | |
| 247,928 | |
Accumulated deficit | |
| (608,940 | ) | |
| (536,755 | ) |
Total stockholders' equity | |
| 294,068 | | |
| 215,608 | |
About Protagonist
Protagonist Therapeutics is a biopharmaceutical
company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development,
both derived from the Company's proprietary technology platform. Protagonist scientists jointly discovered PN-235 (now known as JNJ-2113)
as part of Protagonist’s Interleukin-23 receptor (IL-23R) collaboration with Janssen and followed it through IND-enabling pre-clinical
and Phase 1 studies, with Janssen assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone
hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program. The Phase 2 REVIVE study is now complete,
with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing. Protagonist retains
all worldwide development and commercialization rights to rusfertide.
More information on Protagonist,
its pipeline drug candidates and clinical studies can be found on the Company's website at protagonist-inc.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
include statements regarding the potential benefits of JNJ-2113, our expectations regarding the clinical development of JNJ-2113, our
potential receipt of milestone and royalty payments under our collaboration agreement with Janssen Biotech, Inc., our forecasted
cash runway and our expectations regarding enrollment in the REVIVE Phase 3 trial. In some cases, you can identify these statements by
forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the
negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are
subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including,
but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our
collaboration agreement with Janssen Biotech, Inc., our ability to use and expand our programs to build a pipeline of product candidates,
our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and
compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual
property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can
be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained
in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking
statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release.
Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation
to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press
release.
Contact
Jami Taylor
Email: j.taylor@ptgx-inc.com
v3.23.2
Cover
|
Aug. 03, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 03, 2023
|
Entity File Number |
001-37852
|
Entity Registrant Name |
PROTAGONIST THERAPEUTICS, INC.
|
Entity Central Index Key |
0001377121
|
Entity Tax Identification Number |
98-0505495
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
7707 Gateway Blvd.
|
Entity Address, Address Line Two |
Suite 140
|
Entity Address, City or Town |
Newark
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94560-1160
|
City Area Code |
510
|
Local Phone Number |
474-0170
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.00001
|
Trading Symbol |
PTGX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Protagonist Therapeutics (NASDAQ:PTGX)
Historical Stock Chart
From Apr 2024 to May 2024
Protagonist Therapeutics (NASDAQ:PTGX)
Historical Stock Chart
From May 2023 to May 2024